Skip to main content
Erschienen in: Pathology & Oncology Research 3/2017

23.12.2016 | Original Article

Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival

verfasst von: Christian Niedworok, Stephan Tschirdewahn, Henning Reis, Nils Lehmann, Miklós Szücs, Péter Nyirády, Imre Romics, Herbert Rübben, Tibor Szarvas

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Better prognostication of clinically localized prostate cancer (PCA) is urgently needed. Former studies using different study end-points provided controversial results regarding the prognostic value of serum chromogranin A (CGA) in clinically localized PCA. However, serum CGA was not tested for correlation with the most significant study end-point of long-term disease-specific survival (DSS). CGA and matrix metalloproteinase-7 (MMP7) levels were measured by the BRAHMS KRYPTOR in two independent patient groups with 127 serum and 110 plasma samples. CGA and MMP7 concentrations were correlated with clinicopathological and survival data. In addition, we tested the combinations of CGA with PSA and with a currently identified prognostic factor, MMP7, for their prognostic value. CGA concentrations were significantly elevated in advanced compared to clinically localized cases both in serum and plasma samples (45 vs. 23 ng/ml, p < 0.001 and; 41 vs. 22 ng/ml; p = 0.002 respectively). In accordance, high CGA levels were correlated with poor DSS. In clinically localized cases, CGA levels alone were not prognostic, but its dichotomized combinations with PSA or MMP7 were independently associated with DSS (HR: 4.88, 95% CI: 1.35–17.71, p = 0.016, HR: 7.46, 1.65–33.63, p = 0.009, respectively). Elevated serum CGA levels in progressed PCA and its prognostic value suggest a potential for CGA in disease monitoring. Our results revealed no independent prognostic value for CGA as a single serum marker in clinically localized cases. However, when combining with PSA or MMP7, CGA may improve both marker’s performance in distinguishing between clinically significant and indolent PCAs.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Xu J, Ward E (2011) Cancer statistics, 2010. CA Cancer J Clin 61:133–134CrossRef Jemal A, Siegel R, Xu J, Ward E (2011) Cancer statistics, 2010. CA Cancer J Clin 61:133–134CrossRef
2.
Zurück zum Zitat Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A (2014) ERSPC investigators. Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027–2035CrossRefPubMedPubMedCentral Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A (2014) ERSPC investigators. Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027–2035CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Nesland JM, Holm R, Johannessen JV, Gould VE (1988) Neuroendocrine differentiation in breast lesions. Pathol Res Pract 183:214–221CrossRefPubMed Nesland JM, Holm R, Johannessen JV, Gould VE (1988) Neuroendocrine differentiation in breast lesions. Pathol Res Pract 183:214–221CrossRefPubMed
4.
5.
Zurück zum Zitat O’Connor DT, Deftos LJ (1986) Secretion of chromogranin a by peptide-producing endocrine neoplasms. N Engl J Med 314:1145–1151CrossRefPubMed O’Connor DT, Deftos LJ (1986) Secretion of chromogranin a by peptide-producing endocrine neoplasms. N Engl J Med 314:1145–1151CrossRefPubMed
6.
Zurück zum Zitat Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, Tomassetti P (2007) Chromogranin a: is it a useful marker of neuroendocrine tumors? J Clin Oncol 25:1967–1973CrossRefPubMed Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, Tomassetti P (2007) Chromogranin a: is it a useful marker of neuroendocrine tumors? J Clin Oncol 25:1967–1973CrossRefPubMed
7.
Zurück zum Zitat Khan MO, Ather MH (2011) Chromogranin A--serum marker for prostate cancer. J Pak Med Assoc 61:108–111PubMed Khan MO, Ather MH (2011) Chromogranin A--serum marker for prostate cancer. J Pak Med Assoc 61:108–111PubMed
8.
Zurück zum Zitat Szarvas T, Becker M, Vom Dorp F, Meschede J, Scherag A, Bánkfalvi A, Reis H, Schmid KW, Romics I, Rübben H, Ergün S (2011) Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. Int J Cancer 128:1486–1492CrossRefPubMed Szarvas T, Becker M, Vom Dorp F, Meschede J, Scherag A, Bánkfalvi A, Reis H, Schmid KW, Romics I, Rübben H, Ergün S (2011) Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. Int J Cancer 128:1486–1492CrossRefPubMed
9.
Zurück zum Zitat Sciarra A, Voria G, Monti S, Mazzone L, Mariotti G, Pozza M, D’Eramo G, Silverio FD (2004) Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin a. Prostate 58:421–428CrossRefPubMed Sciarra A, Voria G, Monti S, Mazzone L, Mariotti G, Pozza M, D’Eramo G, Silverio FD (2004) Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin a. Prostate 58:421–428CrossRefPubMed
10.
Zurück zum Zitat Alessandro S, Vincenzo G, Maria AG, Stefano S, Alessandro G, Salvatore M, Vincenzo T, Franco DS (2007) Chromogranin a and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy. Endocr Relat Cancer 14:625–632CrossRefPubMed Alessandro S, Vincenzo G, Maria AG, Stefano S, Alessandro G, Salvatore M, Vincenzo T, Franco DS (2007) Chromogranin a and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy. Endocr Relat Cancer 14:625–632CrossRefPubMed
11.
Zurück zum Zitat De Nunzio C, Albisinni S, Presicce F, Lombardo R, Cancrini F, Tubaro A (2014) Serum levels of chromogranin a are not predictive of high-grade, poorly differentiated prostate cancer: results from an Italian biopsy cohort. Urol Oncol 32:80–84CrossRefPubMed De Nunzio C, Albisinni S, Presicce F, Lombardo R, Cancrini F, Tubaro A (2014) Serum levels of chromogranin a are not predictive of high-grade, poorly differentiated prostate cancer: results from an Italian biopsy cohort. Urol Oncol 32:80–84CrossRefPubMed
12.
Zurück zum Zitat Niedworok C, Vom Dorp F, Tschirdewahn S, Rübben H, Reis H, Szucs M, Szarvas T (2016) Validation of the diagnostic and prognostic relevance of serum MMP7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method. Int Urol Nephrol 48:355–361CrossRefPubMed Niedworok C, Vom Dorp F, Tschirdewahn S, Rübben H, Reis H, Szucs M, Szarvas T (2016) Validation of the diagnostic and prognostic relevance of serum MMP7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method. Int Urol Nephrol 48:355–361CrossRefPubMed
13.
Zurück zum Zitat Krabbe JG, Monaghan PJ, Russell J, de Rijke YB (2016) Analytical evaluation of a second generation assay for chromogranin a; a dual-site study. Clin Chem Lab Med 54:e139–e142CrossRefPubMed Krabbe JG, Monaghan PJ, Russell J, de Rijke YB (2016) Analytical evaluation of a second generation assay for chromogranin a; a dual-site study. Clin Chem Lab Med 54:e139–e142CrossRefPubMed
14.
Zurück zum Zitat Mathis G (1993) Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin Chem 39:1953–1959PubMed Mathis G (1993) Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin Chem 39:1953–1959PubMed
15.
Zurück zum Zitat Sobin LHG, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant Tumours. 7th ed. Wiley-Blackwell, Hoboken Sobin LHG, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant Tumours. 7th ed. Wiley-Blackwell, Hoboken
16.
Zurück zum Zitat Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM, Angeli A, Dogliotti L (2005) Independent prognostic role of circulating chromogranin a in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 12:109–117CrossRefPubMed Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM, Angeli A, Dogliotti L (2005) Independent prognostic role of circulating chromogranin a in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 12:109–117CrossRefPubMed
17.
Zurück zum Zitat Burgio SL, Conteduca V, Menna C, Carretta E, Rossi L, Bianchi E, Kopf B, Fabbri F, Amadori D, De Giorgi U (2014) Chromogranin a predicts outcome in prostate cancer patients treated with abiraterone. Endocr Relat Cancer 21:487–493CrossRefPubMed Burgio SL, Conteduca V, Menna C, Carretta E, Rossi L, Bianchi E, Kopf B, Fabbri F, Amadori D, De Giorgi U (2014) Chromogranin a predicts outcome in prostate cancer patients treated with abiraterone. Endocr Relat Cancer 21:487–493CrossRefPubMed
18.
Zurück zum Zitat Conteduca V, Burgio SL, Menna C, Carretta E, Rossi L, Bianchi E, Masini C, Amadori D, De Giorgi U (2014) Chromogranin a is a potential prognostic marker in prostate cancer patients treated with enzalutamide. Prostate 74:1691–1696CrossRefPubMed Conteduca V, Burgio SL, Menna C, Carretta E, Rossi L, Bianchi E, Masini C, Amadori D, De Giorgi U (2014) Chromogranin a is a potential prognostic marker in prostate cancer patients treated with enzalutamide. Prostate 74:1691–1696CrossRefPubMed
19.
Zurück zum Zitat Harrell FE Jr (2001) Regression modelling strategies with applications to linear models, logistic regression, and survival analysis. Springer, New York Harrell FE Jr (2001) Regression modelling strategies with applications to linear models, logistic regression, and survival analysis. Springer, New York
Metadaten
Titel
Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival
verfasst von
Christian Niedworok
Stephan Tschirdewahn
Henning Reis
Nils Lehmann
Miklós Szücs
Péter Nyirády
Imre Romics
Herbert Rübben
Tibor Szarvas
Publikationsdatum
23.12.2016
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2017
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0171-5

Weitere Artikel der Ausgabe 3/2017

Pathology & Oncology Research 3/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.